HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Thomas M Schmitt Selected Research

Neoplasms (Cancer)

1/2022Targeting an alternate Wilms' tumor antigen 1 peptide bypasses immunoproteasome dependency.
1/2018Comparison of T Cell Activities Mediated by Human TCRs and CARs That Use the Same Recognition Domains.
12/2017Generation of higher affinity T cell receptors by antigen-driven differentiation of progenitor T cells in vitro.
8/2017The miR-106a~363Xpcl1 miRNA cluster induces murine T cell lymphoma despite transcriptional activation of the p27Kip1 cell cycle inhibitor.
2/2017Tracking the Fate and Origin of Clinically Relevant Adoptively Transferred CD8+ T Cells In Vivo.
12/2015New Strategies in Engineering T-cell Receptor Gene-Modified T cells to More Effectively Target Malignancies.
1/2014Re-adapting T cells for cancer therapy: from mouse models to clinical trials.
7/2013Enhanced-affinity murine T-cell receptors for tumor/self-antigens can be safe in gene therapy despite surpassing the threshold for thymic selection.
8/2012Abrogation of SRC homology region 2 domain-containing phosphatase 1 in tumor-specific T cells improves efficacy of adoptive immunotherapy by enhancing the effector function and accumulation of short-lived effector T cells in vivo.
11/2010The B-cell tumor-associated antigen ROR1 can be targeted with T cells modified to express a ROR1-specific chimeric antigen receptor.
For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Thomas M Schmitt Research Topics

Disease

12Neoplasms (Cancer)
01/2022 - 04/2009
5Leukemia
01/2019 - 04/2009
3Wilms Tumor (Wilm's Tumor)
01/2022 - 02/2013
2Acute Myeloid Leukemia (Acute Myelogenous Leukemia)
01/2022 - 01/2019
1Graft vs Host Disease (Graft-Versus-Host Disease)
01/2019
1T-Cell Lymphoma (Lymphoma, T Cell)
08/2017
1Lymphoma (Lymphomas)
08/2017
1Adenocarcinoma
11/2015
1Mantle-Cell Lymphoma (Lymphoma, Mantle Cell)
11/2010
1B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia)
11/2010

Drug/Important Bio-Agent (IBA)

8AntigensIBA
01/2022 - 04/2009
6T-Cell Antigen Receptors (T-Cell Receptor)IBA
01/2022 - 04/2009
4Proteins (Proteins, Gene)FDA Link
01/2019 - 08/2012
3AutoantigensIBA
12/2017 - 08/2012
2Peptides (Polypeptides)IBA
01/2022 - 01/2018
2Interleukin-2 (IL2)IBA
11/2017 - 08/2012
2Neoplasm Antigens (Tumor Antigens)IBA
07/2013 - 04/2009
1WT1 ProteinsIBA
01/2022
1HLA Antigens (Human Leukocyte Antigens)IBA
01/2022
1EpitopesIBA
01/2022
1CytokinesIBA
11/2017
1MicroRNAs (MicroRNA)IBA
08/2017
1HLA-A*02:01 antigenIBA
02/2013
1Transcription Factors (Transcription Factor)IBA
02/2013
1Phosphoric Monoester Hydrolases (Phosphatases)IBA
08/2012
1Small Interfering RNA (siRNA)IBA
08/2012
1Monoclonal AntibodiesIBA
11/2010
1Chimeric Antigen ReceptorsIBA
11/2010
1Receptor Tyrosine Kinase-like Orphan ReceptorsIBA
11/2010
1Pharmaceutical PreparationsIBA
11/2010

Therapy/Procedure

9Therapeutics
01/2019 - 11/2009
4Immunotherapy
01/2022 - 04/2009
2Cell Transplantation
01/2019 - 02/2013
2Drug Therapy (Chemotherapy)
11/2015 - 11/2010